急诊住院背景下血浆二甲双胍浓度与乳酸酸中毒及死亡率的相关性研究
该回顾性、观察性、单中心研究纳入194例急诊住院的二甲双胍治疗糖尿病患者,87例(44.8%)存在乳酸酸中毒(动脉血pH<7.35且乳酸≥4 mM),其中38例(43.7%)在ICU死亡。ROC曲线分析显示血浆二甲双胍浓度阈值9.9 mg/L与乳酸酸中毒发生显著相关(特异性92.9%,敏感性67.1%,AUC 0.83,P<0.0001)。在乳酸酸中毒阳性患者中,二甲双胍浓度≥9.9 mg/L者ICU死亡较少(33.9% vs <9.9 mg/L者61.3%,P=0.0252)。校正SAPS II后,ICU死亡与凝血酶原活动度<70%正相关,与入院时启动肾脏替代治疗负相关。
要点
- 急诊住院的二甲双胍治疗患者中,血浆二甲双胍浓度≥9.9 mg/L与乳酸酸中毒强烈相关(特异性92.9%,敏感性67.1%,AUC 0.83,P<0.0001)。
- 乳酸酸中毒定义为动脉血pH<7.35且乳酸浓度≥4 mM;本队列87例(44.8%)符合,其中38例(43.7%)在ICU死亡。
- 乳酸酸中毒阳性患者中,二甲双胍浓度≥9.9 mg/L者ICU死亡率33.9%,低于<9.9 mg/L者的61.3%(P=0.0252)。
- 校正SAPS II后,ICU死亡与凝血酶原活动度<70%正相关,与入院时启动肾脏替代治疗负相关。
- 作者认为该阈值可能辅助决定是否启动肾脏替代治疗,乳酸酸中毒结局可能取决于及时启动肾脏替代治疗,尤其当肝衰竭减少乳酸清除时。
适用人群与场景
- 连续纳入9.7年期间在法国亚眠大学医院急诊科和ICU住院、入院24小时内行血浆二甲双胍检测、且在检测前后12小时内行动脉血乳酸和pH检测的二甲双胍治疗糖尿病患者,共194例(中位年龄68.6岁,男性113例[58.2%])。
诊断标准与关键阈值
- 乳酸酸中毒定义:动脉血pH<7.35且乳酸浓度≥4 mM。
- 血浆二甲双胍浓度阈值9.9 mg/L与乳酸酸中毒发生显著相关(特异性92.9%,敏感性67.1%,AUC 0.83,P<0.0001)。
红旗征与不能漏的情况
- 乳酸酸中毒(动脉血pH<7.35且乳酸≥4 mM)患者ICU死亡率为43.7%(38/87)。
- 凝血酶原活动度<70%与ICU死亡正相关(校正SAPS II后)。
研究设计与关键结果
- 研究设计:回顾性、观察性、单中心研究,纳入194例急诊住院的二甲双胍治疗糖尿病患者。
- 163例(84%)存在急性肾损伤,分别与脱水(45.4%)、脓毒症(41.1%)、心源性休克(20.9%)、糖尿病酮症酸中毒(16%)相关。
- 87例(44.8%)存在乳酸酸中毒,其中38例(43.7%)在ICU死亡。
- ROC曲线分析:二甲双胍浓度阈值9.9 mg/L与乳酸酸中毒发生显著相关(特异性92.9%,敏感性67.1%,AUC 0.83,P<0.0001)。
- 乳酸酸中毒阳性患者中,二甲双胍浓度≥9.9 mg/L者ICU死亡率33.9%,低于<9.9 mg/L者的61.3%(P=0.0252)。
- 校正SAPS II后,ICU死亡与凝血酶原活动度<70%正相关,与入院时启动肾脏替代治疗负相关。
证据类型、等级与局限
- 证据类型:回顾性、观察性、单中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在急诊住院的二甲双胍治疗糖尿病患者中,血浆二甲双胍浓度≥9.9 mg/L强烈关联乳酸酸中毒,该阈值可能辅助决定是否启动肾脏替代治疗。
- 作者认为乳酸酸中毒结局可能取决于及时启动肾脏替代治疗,尤其当肝衰竭减少乳酸清除时。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the plasma metformin concentration threshold associated with lactic acidosis and analyze the outcome in metformin-treated patients with lactic acidosis hospitalized in an emergency context.
DESIGN: A retrospective, observational, single-center study.
SETTING: Emergency department and ICUs at Amiens University Hospital (Amiens, France).
PATIENTS: All consecutive patients with data on arterial lactate and pH up to 12 hours before or after a plasma metformin assay within 24 hours of admission, over a 9.7-year period.
MEASUREMENTS AND MAIN RESULTS: The study population consisted of 194 metformin-treated diabetic patients (median age: 68.6; males: 113 [58.2%]); 163 (84%) had acute kidney injury, which was associated variously with dehydration (45.4%), sepsis (41.1%), cardiogenic shock (20.9%), and diabetic ketoacidosis (16%). Eighty-seven patients (44.8%) had lactic acidosis defined as an arterial blood pH less than 7.35 and a lactate concentration greater than or equal to 4 mM, and 38 of them (43.7%) died in the ICU. A receiver operating characteristic curve analysis showed that a metformin concentration threshold of 9.9 mg/L was significantly associated with the occurrence of lactic acidosis (specificity: 92.9%; sensitivity: 67.1%; area under the receiver operating characteristic curve: 0.83; p < 0.0001). Among lactic acidosis-positive patients, however, in-ICU death was less frequent when the metformin concentration was greater than or equal to 9.9 mg/L (33.9% vs 61.3% for < 9.9 mg/L; p = 0.0252). After adjustment for the Simplified Acute Physiology Score II, in-ICU death was positively associated with prothrombin activity less than 70% and negatively associated with the initiation of renal replacement therapy at admission.
CONCLUSIONS: In metformin-treated patients admitted in an emergency context, a plasma metformin concentration greater than or equal to 9.9 mg/L was strongly associated with the presence of lactic acidosis. This threshold may assist with the delicate decision of whether or not to initiate renal replacement therapy. Indeed, the outcome of lactic acidosis might depend on the prompt initiation of renal replacement therapy-especially when liver failure reduces lactate elimination.
参考来源
- Bennis Y, Bodeau S, Batteux B, et al. A Study of Associations Between Plasma Metformin Concentration, Lactic Acidosis, and Mortality in an Emergency Hospitalization Context. Crit Care Med. 2020. PMID: 33003077. doi:10.1097/CCM.0000000000004589
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。